News

Los Angeles-A randomized, controlled trial comparing the combination therapy dorzolamide-timolol (Cosopt, Merck) with concomitant administration of 2% dorzolamide (Trusopt, Merck) and 0.5% timolol showed that the IOP lowering is equally effective if the drugs are given either in combination or individually.

Houston-In patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH), once-daily treatment with fixed-combination latanoprost/timolol (Xalacom, Pharmacia, Peapack, NJ) is well tolerated and lowers IOP more effectively than twice-daily dorzolamide/timolol (Cosopt, Merck), according to a recent multicenter U.S. study.

Baltimore-Latanoprost 0.005% (Xalatan, Pharmacia) taken once daily is more effective in lowering IOP than unoprostone 0.15% (Rescula, Novartis) taken twice daily, according to a recent multicenter study, reported Henry D. Jampel, MD, MHS.

Houston-Once-daily bimatoprost 0.03% (Lumigan, Allergan) is a highly effective, safe, and well-accepted IOP-lowering medication across the di-verse population of patients encountered in daily practice, according to the results of a large-scale, com-munity-based, pro-spective, open-label study.

Tucson, AZ-Topical beta-blockers have been a mainstay of ongoing treatment for glaucoma for more than 20 years, but a new study adds to the evidence that they may not be the best option for long-term control of IOP for elderly patients.

Editor's note: This is the second story in a three-part series covering a forum on "Ethnicity and Glaucoma" at Johns Hopkins University to commemorate the 20th anniversary of the Baltimore Eye Study. The meeting was sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times and supported through an unrestricted educational grant from Alcon Laboratories Inc.

La Jolla, CA-Results from murine studies indicate that a population of adult bone marrow-derived hematopoietic stem cells injected intravitreally will selectively target activated astrocytes, become incorporated into blood vessels, and promote or inhibit retinal angiogenesis, reported Martin Friedlander, MD, PhD.

Nice, France-With the introduction of new implantation devices, the AcrySof IOL (Alcon, Fort Worth, TX) is now much easier to manipulate compared with previously. Takayuki Akahoshi, MD, director of ophthalmology, Mitsui Memorial Hospital, Tokyo, Japan, introduced the new implantation devices here at the XX Congress of the European Society of Cataract and Refractive Surgeons.

The new LASIK Certification Program developed by the American Board of Eye Surgery (ABES) is seen as being a long time coming and an important step in the right direction for the entire field of medicine.

Eye-Tech Training

Nice, France-Computer-simulated phaco takes advantage of the advances in computer power and graphics to develop simulators to train surgeons in cataract surgery. This technology might serve as a tool for surgical training or be used by medical students during basic medical education to stimulate student interest in surgery and to test their skills.

New York-Glaucoma therapy of 10 years ago has no application today, according to Robert D. Fechtner, MD, who opened a session on glaucoma and cataract surgery at the Glaucoma 2002 meeting here.

Los Angeles-Considering the limited availability of published randomized trials, glaucoma surgeons should remain skeptical about the safety and efficacy of viscocanalostomy and deep sclerectomy with collagen wick, said Donald S. Minckler, MD.

Rome, Italy-The implantation of the AT-45 CrystaLens accommodating IOL (C & C Vision, Aliso Viejo, CA) through a corneal tunnel resulted in disappointing outcomes in patients with 2 D or more of astigmatism. The outcomes differed for patients with against-the-rule astigmatism compared with those who had with-the-rule astigmatism, and there was no predictability in the procedure, according to Scipione Rossi, MD.

Editor's Note: It has been a great pleasure and an honor to have been able to work with the editorial staff of Ophthalmology Times in creating the Cataract Corner column over the past 5 years. However, at this time I take equal pleasure in turning over the column to my two associates, Dr. Richard Hoffman and Dr. Mark Packer, both of whom are superb surgeons, excellent clinicians, great speakers, and experienced researchers. They represent the next generation of leadership in cataract and refractive surgery, and I'm sure the readers of this column will enjoy their perspective and input as they

Ann Arbor, MI-Results from gene microarray studies by researchers at the University of Michigan reveal there are highly specific, age-related changes in retinal gene expression. Those findings are described in the August issue of Investigative Ophthalmology and Visual Science [Yoshida S, et al. IVOS 2002; 43:2554-2560].

Fort Myers, FL-A comparison of two laser systems, the STAR S2 (VISX, Santa Clara, CA) and the LadarVision (Alcon, Fort Worth, TX), used to treat low to moderate levels of myopia indicated that the visual results after LASIK were similar between the two but that visual recovery appeared to be faster with the STAR S2.

A 42-year-old Hispanic male presented complaining of decreased vision in his left eye. He noted that his vision in that eye had decreased suddenly three weeks earlier. The patient had low hyperopia. His medical, surgical, and family histories were unremarkable. He was using no medications and had no known drug allergies. Although he initially reported no significant social history, after more extensive questioning he admitted to the occasional inhalational use of cocaine. His most recent use was on the day prior to the onset of his visual disturbance.

San Diego-Several higher-order aberrations have been correlated with patients' visual complaints after LASIK. Because wavefront technology appears to reduce the induction of higher-order aberrations after LASIK, wavefront-guided ablations may improve the visual outcomes after LASIK, according to Steven C. Schallhorn, MD.

Atlanta-The risk of corneal ectasia following LASIK is greater in patients with form fruste keratoconus, more than -8 D of myopia, and residual stromal beds that are thinner than 225 ?m. Most of the patients who developed corneal ectasia, however, were able to obtain a good visual outcome with contact lens correction, according to R. Doyle Stulting, MD, PhD.

Rockville Centre, NY-Implantation of a posterior chamber phakic refractive lens (PRL) (Medennium phakic refractive lens, CIBA Vision, Duluth, GA) demonstrated positive visual outcomes in the treatment of high hyperopia, according to Alexander Hatsis, MD, who presented the results of the FDA phase II trial.